Goodwin Procter LLP advised ImmuNext Inc. on its option and license agreement with Curis, Inc. (NASDAQ: CRIS). Curis, Inc., a biotechnology company focused on the development…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now